Breaking Down SG&A Expenses: argenx SE vs Perrigo Company plc

A Tale of Two Companies: SG&A Expenses Over Time

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent companies: argenx SE and Perrigo Company plc, from 2014 to 2023.

Perrigo Company plc, a stalwart in the industry, consistently allocated a significant portion of its budget to SG&A expenses, peaking at approximately $1.27 billion in 2023. This represents a steady increase of around 89% from its 2014 figures. In contrast, argenx SE, a rising star, exhibited a remarkable growth trajectory, with its SG&A expenses skyrocketing from a modest $4.2 million in 2014 to an impressive $709 million in 2023, marking an exponential increase of over 16,600%.

This stark contrast highlights the differing growth strategies and market positions of these two companies, offering valuable insights into their operational priorities and financial health.